Larimar Therapeutics Inc (LRMR)

May 21, 2026

Larimar Therapeutics Stock Slumps Pre-market Over High Anaphylaxis Rate In Drug Study - MSN

May 21, 2026

May 20, 2026

[Form 4] Larimar Therapeutics, Inc. Insider Trading Activity - Stock Titan

May 20, 2026

May 20, 2026

Larimar Therapeutics (LRMR) entity tied to director receives 55,150 stock options - Stock Titan

May 20, 2026

May 20, 2026

Larimar Therapeutics (LRMR) awards 55,150 stock options to director - Stock Titan

May 20, 2026

May 20, 2026

Larimar Therapeutics (LRMR) director receives 55,150 stock options grant - Stock Titan

May 20, 2026

May 20, 2026

Larimar Therapeutics (LRMR) director awarded 55,150 stock options at $3.33 strike - Stock Titan

May 20, 2026

May 20, 2026

Larimar Therapeutics (LRMR) director gets 55,150 stock options at $3.33 strike - Stock Titan

May 20, 2026

May 20, 2026

Larimar Therapeutics stockholders approve board elections and share increase By Investing.com - Investing.com Nigeria

May 20, 2026

May 19, 2026

Larimar Therapeutics stockholders approve board elections and share increase - Investing.com

May 19, 2026

May 19, 2026

Larimar Shareholders Approve Governance and Capital Structure Changes - TipRanks

May 19, 2026

May 19, 2026

Larimar Therapeutics (NASDAQ: LRMR) holders back big authorized share increase - Stock Titan

May 19, 2026

May 18, 2026

LRMR Maintained by Wedbush -- Price Target Lowered to $12.00 - GuruFocus

May 18, 2026

May 18, 2026

Wedbush Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $12 - Moomoo

May 18, 2026

May 18, 2026

Larimar Therapeutics Price Target Cut to $12.00/Share From $13.00 by Wedbush - Moomoo

May 18, 2026

May 16, 2026

Larimar Therapeutics (LRMR) surges on FDA breakthrough therapy designation - MSN

May 16, 2026

May 16, 2026

Wedbush Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Cuts Target Price to $12 - Moomoo

May 16, 2026

May 15, 2026

Number of shareholders of Larimar Therapeutics, Inc. – NASDAQ:LRMR - TradingView

May 15, 2026

May 15, 2026

Wedbush Adjusts Larimar Therapeutics Price Target to $12 From $13, Maintains Outperform Rating - Moomoo

May 15, 2026

May 15, 2026

Larimar Details Q1 Results and Nomlabofusp Regulatory Progress - The Globe and Mail

May 15, 2026

May 15, 2026

Exploring US High Growth Tech Stocks This May 2026 - Yahoo Finance

May 15, 2026

May 15, 2026

Citizens reiterates Larimar Therapeutics stock rating on FDA progress By Investing.com - Investing.com South Africa

May 15, 2026

May 15, 2026

Citizens reiterates Larimar Therapeutics stock rating on FDA progress - Investing.com India

May 15, 2026

May 14, 2026

Larimar Therapeutics, Inc. Stock 12‑Month Price Target Cut to $15.88, Implies 287% Upside - TradingView

May 14, 2026

May 14, 2026

LARIMAR THERAPEUTICS (LRMR) Advances towards Friedreich's Ataxia Treatment Approval - GuruFocus

May 14, 2026

May 14, 2026

Blue Owl (NASDAQ: LRMR) discloses 9.99% position totaling 10.74M shares - Stock Titan

May 14, 2026

May 14, 2026

Larimar Therapeutics (LRMR) lifts cash to $200M as FDA grants Breakthrough status - Stock Titan

May 14, 2026

May 14, 2026

Larimar Therapeutics 1Q Research and Development Expenses $25.0M >LRMR - Moomoo

May 14, 2026

May 14, 2026

Larimar Therapeutics Advances Nomlabofusp for Friedreich’s Ataxia with Rolling BLA Submission and Strong Q1 2026 Financials - Minichart

May 14, 2026

May 14, 2026

Larimar Therapeutics Releases Q1 2026 Financial Results - AlphaStreet

May 14, 2026

May 14, 2026

LRMR: Nomlabofusp shows strong efficacy and safety in FA, targeting 2027 U.S. launch - TradingView

May 14, 2026

May 14, 2026

Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update - The Manila Times

May 14, 2026

May 14, 2026

Larimar: Q1 Earnings Snapshot - KTVB

May 14, 2026

May 14, 2026

Larimar Therapeutics (LRMR) boosts cash, eyes 2027 launch for FA therapy - Stock Titan

May 14, 2026

May 14, 2026

BRIEF-Larimar Therapeutics Q1 Net Income USD -29.613 Million - TradingView

May 14, 2026

May 12, 2026

MSN Money - MSN

May 12, 2026

May 12, 2026

TradingKey - TradingKey

May 12, 2026

May 08, 2026

LRMR (Larimar Therapeutics) Q4 loss widens 41% miss as drug development costs climb; shares edge lower.Investment Signal Network - newser.com

May 08, 2026

May 08, 2026

LRMR SEC FilingsLarimar Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

May 08, 2026

May 06, 2026

Larimar Data Support Surrogate Endpoint for Nomlabofusp Approval Path - MyChesCo

May 06, 2026

May 02, 2026

Analysts Offer Insights on Healthcare Companies: Stryker (SYK) and Larimar Therapeutics (LRMR) - The Globe and Mail

May 02, 2026

May 02, 2026

Larimar Therapeutics, Inc. $LRMR Shares Acquired by AIGH Capital Management LLC - MarketBeat

May 02, 2026

May 01, 2026

LRMR Forecast, Price Target & Analyst Ratings | LARIMAR THERAPEUTICS INC (NASDAQ:LRMR) - ChartMill

May 01, 2026

Apr 30, 2026

Millennium Management (LRMR) reports 3.5% ownership; 3,625,278 shares - Stock Titan

Apr 30, 2026

Apr 30, 2026

Larimar Therapeutics Publishes Cross-Species Findings - GlobeNewswire

Apr 30, 2026

Apr 27, 2026

Larimar Therapeutics stock dips after pricing $100M share offering - MSN

Apr 27, 2026

Apr 27, 2026

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Apr 27, 2026

Apr 26, 2026

Larimar Therapeutics launches proposed $75 million public offering - MSN

Apr 26, 2026

Apr 25, 2026

LRMR stock on the move: What sparked the 55% jump in the past month? - MSN

Apr 25, 2026

Apr 24, 2026

Larimar Therapeutics Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView

Apr 24, 2026